Recurrent Non-Small Cell Lung Carcinoma Clinical Trial
Official title:
Phase II Trial of XL184 (Cabozantinib) Plus Erlotinib in Patients With Advanced EGFR-Mutant Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy
This phase II trial studies how well cabozantinib-s-malate and erlotinib hydrochloride works in treating patients with previously treated metastatic non-small cell lung cancer. Cabozantinib-s-malate and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cabozantinib-s-malate may also stop the growth of non-small cell lung cancer by blocking blood flow to the tumor. Giving cabozantinib-s-malate together with erlotinib hydrochloride may be an effective treatment for non-small cell lung cancer.
PRIMARY OBJECTIVES:
I. To evaluate for efficacy by response rate (RR) when patients with advanced non-small cell
lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation who have
progressed following EGFR tyrosine kinase inhibitor (TKI) therapy are treated with XL184
(cabozantinib [cabozantinib-s-malate]) and erlotinib (erlotinib hydrochloride).
SECONDARY OBJECTIVES:
I. Determine progression free survival (PFS) for combination XL184 (cabozantinib) and
erlotinib in EGFR mutation positive patients following progression on erlotinib.
II. Assess overall survival. III. Evaluate change in tumor growth rate on XL184
(cabozantinib) and erlotinib.
IV. Evaluate type, severity, duration and outcome of toxicities. V. Correlate outcome with
tumor biomarkers such as met proto-oncogene (MET) amplification, T790M mutation, and serum
markers of the vascular endothelial growth factor (VEGF) and MET pathways in a preliminary
manner.
OUTLINE:
Patients receive cabozantinib-s-malate orally (PO) daily and erlotinib hydrochloride PO once
daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression
or unacceptable toxicity.
After completion of study treatment, patients are followed up every 12 weeks for 1 year and
then annually thereafter.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02364609 -
Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib
|
Phase 1 | |
| Terminated |
NCT02495896 -
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Withdrawn |
NCT01971489 -
Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT00963807 -
Trial Comparing the Use of FLT PET to Standard CT to Assess Treatment Response of Neoadjuvant Docetaxel and Cisplatin in Stage IB-IIIA Resectable NSCLC
|
Phase 2 | |
| Terminated |
NCT00096265 -
Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer
|
Phase 3 | |
| Terminated |
NCT02566421 -
Genomic Sequencing in Determining Treatment in Patients With Metastatic Cancer or Cancer That Cannot Be Removed by Surgery
|
N/A | |
| Terminated |
NCT00738881 -
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT02438722 -
S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer
|
Phase 2/Phase 3 | |
| Terminated |
NCT02408016 -
Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
|
Phase 1/Phase 2 | |
| Terminated |
NCT01935947 -
Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT01131234 -
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT01737502 -
Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT00955305 -
Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03049618 -
Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475
|
Phase 2 | |
| Terminated |
NCT02949843 -
Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations
|
Phase 2 | |
| Completed |
NCT02947386 -
Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT02819024 -
Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission Tomography
|
N/A | |
| Withdrawn |
NCT02451865 -
Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer
|
Phase 1 | |
| Completed |
NCT02581943 -
Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT02846792 -
Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer
|
Phase 1/Phase 2 |